OverviewSuggest Edit

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. The Company has developed a proprietary technology that is designed to deliver a drug that is retained in the ear for an extended period of time following a single local administration. Utilizing this technology, Otonomy has advanced multiple product candidates into development and launched its first product, OTIPRIO®.

OTIPRIO is a single-dose, physician-administered antibacterial and the first product approved by the FDA for the treatment of pediatric patients with bilateral otitis media with effusion undergoing ear tube placement.

TypePublic
Founded2008
HQSan Diego, US
Websiteotonomy.com

Latest Updates

Employees (est.) (Dec 2018)49(-7%)
Revenue (FY, 2018)$745 K(-39%)
Share Price (Nov 2019)$2.4 (-2%)

Key People/Management at Otonomy

David A. Weber

David A. Weber

Chief Executive Officer, President and Board Member
Elizabeth J. Ackermann

Elizabeth J. Ackermann

Vice President, Clinical Development
Carla da Luz Boren

Carla da Luz Boren

General Counsel and Head of Human Resources
Julie D. Burgess

Julie D. Burgess

Vice President, Finance and Administration
Paul E. Cayer

Paul E. Cayer

Chief Financial & Business Officer
Barbara M. Finn

Barbara M. Finn

Vice President, Regulatory Affairs and Quality Assurance
Show more

Otonomy Office Locations

Otonomy has an office in San Diego
San Diego, US (HQ)
4796 Executive Dr
Show all (1)

Otonomy Financials and Metrics

Otonomy Revenue

Embed Graph
View revenue for all periods
Otonomy's revenue was reported to be $745 k in FY, 2018 which is a 39.7% decrease from the previous period.
USD

Revenue (Q3, 2019)

125.0k

Gross profit (Q3, 2019)

(95.0k)

Gross profit margin (Q3, 2019), %

(76%)

Net income (Q3, 2019)

(10.0m)

EBIT (Q3, 2019)

(10.1m)

Market capitalization (15-Nov-2019)

74.7m

Closing stock price (15-Nov-2019)

2.4

Cash (30-Sep-2019)

16.3m

EV

73.4m
Otonomy's current market capitalization is $74.7 m.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

683.0k1.2m745.0k

Revenue growth, %

81%(40%)

Cost of goods sold

1.7m3.1m946.0k

Gross profit

(981.0k)(1.9m)(201.0k)
Quarterly
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

24.2m18.5m33.6m

Accounts Receivable

91.0k107.0k108.0k

Inventories

1.4m6.0k

Current Assets

202.2m122.4m100.1m
Quarterly
USDQ1, 2015Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

201.0m13.7m22.3m16.9m23.2m19.0m21.4m16.3m12.1m16.3m

Accounts Receivable

178.0k76.0k126.0k133.0k14.0k45.0k14.0k68.0k33.0k

Prepaid Expenses

4.3m1.5m3.7m

Inventories

1.2m1.2m1.2m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(110.6m)(90.1m)(50.4m)

Depreciation and Amortization

708.0k1.3m1.2m

Inventories

(1.4m)153.0k

Accounts Payable

(2.2m)(398.0k)68.0k
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(27.1m)(71.3m)(11.4m)(25.0m)(37.5m)(12.0m)(23.7m)(33.7m)

Depreciation and Amortization

923.0k295.0k594.0k892.0k276.0k565.0k854.0k

Inventories

1.2m1.2m197.0k6.0k

Accounts Payable

212.0k1.3m138.0k1.5m(184.0k)321.0k123.0k837.0k(90.0k)
USDY, 2019

EV/EBIT

-7.3 x

EV/CFO

-2.5 x

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.8 x
Show all financial metrics

Otonomy Operating Metrics

FY, 2016

Patents Issued

88

Patents Pending

115

Phase III Trials Products

2

Products

1
Show all operating metrics

Otonomy Online and Social Media Presence

Embed Graph

Otonomy News and Updates

AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

Initial focus on GJB2, the most common cause of genetic hearing loss in newborns Initial focus on GJB2, the most common cause of genetic hearing loss in newborns

Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. EDT

Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. EDT

Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication

SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the signing of a co-promotion agreement with Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of …

Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit

SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the company will host one-on-one meetings with investors at the 5th Annual SunTrust Robinson Humphrey …

Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus

Results expected in first half of 2020 Results expected in first half of 2020
Show more

Otonomy Blogs

Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update Content Import Tue, 11/05/2019 - 16:14 Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update November 5, 2019 at 4:13 PM EST This release is a backf…

Otonomy to Present at the Cantor Global Healthcare Conference

Otonomy to Present at the Cantor Global Healthcare Conference Michaela.Delmo… Thu, 09/26/2019 - 16:06 Otonomy to Present at the Cantor Global Healthcare Conference September 26, 2019 at 4:05 PM EDT This release is a backfill from a News Wire Gen…

Associate Scientist, Formulations

Position Objective: Execute formulation development work to support new products, develop drug products to support clinical development programs. Essential Functions: Understand and independently perform high-quality, hands-on experimental design of formulation development Review, compile and docume…

Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update

Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update Content Import Thu, 07/25/2019 - 16:05 Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update Jul 25, 2019 This release is a backfill from a New…

David A. Weber, Ph.D.

Chief Executive Officer, President and Board Member David A. Weber, Ph.D. has served as our President and Chief Executive Officer and on our board of directors since late 2010. Prior to joining us, Dr. Weber served from February 2004 to April 2010 as the Chief Executive Officer of MacuSight, Inc., a…

Otonomy to Present at the Raymond James Life Sciences and MedTech Conference

Otonomy to Present at the Raymond James Life Sciences and MedTech Conference Content Import Wed, 06/12/2019 - 08:01 Otonomy to Present at the Raymond James Life Sciences and MedTech Conference Jun 12, 2019 This release is a backfill from a News Wire …
Show more

Otonomy Frequently Asked Questions

  • When was Otonomy founded?

    Otonomy was founded in 2008.

  • Who are Otonomy key executives?

    Otonomy's key executives are David A. Weber, Elizabeth J. Ackermann and Carla da Luz Boren.

  • How many employees does Otonomy have?

    Otonomy has 49 employees.

  • What is Otonomy revenue?

    Latest Otonomy annual revenue is $745 k.

  • What is Otonomy revenue per employee?

    Latest Otonomy revenue per employee is $15.2 k.

  • Who are Otonomy competitors?

    Competitors of Otonomy include BeyondSpring, Inovio Pharmaceuticals and MyoKardia.

  • Where is Otonomy headquarters?

    Otonomy headquarters is located at 4796 Executive Dr, San Diego.

  • Where are Otonomy offices?

    Otonomy has an office in San Diego.

  • How many offices does Otonomy have?

    Otonomy has 1 office.